Vanguard Group Inc. Sells 20,331 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Vanguard Group Inc. lowered its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,274,638 shares of the company's stock after selling 20,331 shares during the period. Vanguard Group Inc. owned 4.31% of Dianthus Therapeutics worth $27,787,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in shares of Dianthus Therapeutics during the third quarter valued at $556,000. Barclays PLC raised its stake in shares of Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company's stock worth $1,141,000 after buying an additional 33,185 shares during the last quarter. State Street Corp lifted its holdings in Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company's stock valued at $22,483,000 after buying an additional 413,425 shares during the period. Wellington Management Group LLP acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at $1,473,000. Finally, SG Americas Securities LLC grew its stake in shares of Dianthus Therapeutics by 9.2% during the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock worth $210,000 after purchasing an additional 814 shares during the period. Institutional investors own 47.53% of the company's stock.

Analyst Upgrades and Downgrades

DNTH has been the topic of a number of analyst reports. HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush restated an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reiterated a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, TD Cowen began coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a "buy" rating for the company. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $54.33.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH traded up $0.52 during trading hours on Friday, hitting $19.50. The company's stock had a trading volume of 180,937 shares, compared to its average volume of 259,286. Dianthus Therapeutics, Inc. has a twelve month low of $13.37 and a twelve month high of $32.27. The stock has a fifty day simple moving average of $20.32 and a 200-day simple moving average of $23.19. The company has a market capitalization of $626.46 million, a P/E ratio of -7.80 and a beta of 1.62.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.04. The firm had revenue of $1.33 million during the quarter, compared to analysts' expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.